A Phase 2 Pilot Study to Assess ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

• Status: Completed
• Trial end date: 2014-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial will evaluate the effect of ASP7147 on daily abdominal pain due to IBS-D during 4 weeks of treatment. It will also evaluate safety and tolerability in patients with IBS-D over the 4-week treatment period.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seldar Pharma, Inc.

Criteria

Inclusion Criteria:

• Ability to provide written informed consent

• Men or women aged 18-75 years

• Patient has IBS with diarrhea (IBS-D)

• Ability to communicate with the investigator

Exclusion Criteria:

• IBS with constipation (IBS-C) or mixed IBS (IBS-M)

• Other significant disease or condition that may interfere with trial completion

• Untreated lactose intolerance

• History of alcohol or drug abuse in past two years

• Participation in other clinical trials within prior month